Mumbai: Cipla has announced that the United States Food and Drug Administration (USFDA) has classified the inspection at the manufacturing facility of Medispray Laboratories Private Limited, a ...

Cipla’s shares have surged 6% since saying last week it received final approval from the US Food and Drug Administration for its generic version of Bristol Myers Squibb’s Abraxane, a cancer ...

Gold and silver are experiencing substantial growth amid uncertainty over US trade, fiscal policies, geopolitics, and a global economic slowdown, potentially leading to a US recession. (Reuters ...

The Western Cape High Court has interdicted Cipla Medpro from infringing its competitors' trademark. The Western Cape High Court has interdicted Cipla Medpro (Pty) Ltd from passing off its ...

While Cipla may benefit from a revival in generic lanreotide sales (supply issues getting sorted), Lupin may see a gain in its US portfolio from seasonality (flu and antibiotics). The domestic branded ...

The Income Tax Department opened its portal earlier this month for AY 2025-26 — paving the way for first-time taxpayers to file their returns online. The process can prove to be somewhat ...

Cipla is currently priced at Rs 1471.80, reflecting a 0.6% increase today. The stock has impressive 5-year returns of 148.15%, showcasing its strong performance. Cipla is currently priced at Rs ...

Cipla Ltd. has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paclitaxel, a generic version of Bristol Myers Squibb ...

In March 2025, among the top-20 pharma companies as per Motilal Oswal Financial Services, JB Chemicals & Pharmaceutical marked a growth of 17.1% YoY, while Cipla Ltd saw sales grow 16.3% YoY.

Nomura India maintains 'Buy' rating on Cipla with Rs 1,780 target by March 2026. Cipla's Goa site receives USFDA approval for gAbraxane, paving way for FY26 launch. Launch expected in 1HFY26 ...

Cipla’s abbreviated new drug application for a generic version of Bristol Myers Squibb’s cancer drug Abraxane has received final approval from the U.S. Food and Drug Administration. The final ...

Cipla is currently trading at Rs 1463.90, showing a robust increase of 3.42% today. The 7-day exponential moving average at Rs 1495.45 suggests a positive trend in its recent performance. Cipla is ...